chronic obstructive pulmonary disease
Conditions
Interventions
3.2 g/day) or
placebo for 8 - 10 weeks.
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. COPD group B or D (high symptomatic) 2. Grade 2 or higher on the modified Medical Medical Research Council (mMRC) 3. Clinically stable on the basis of clinical picture by pulmonary physician, i.e. no exacerbation and/or hospitalization within the previous 4 weeks 4. Age between 40-80 years 5. Attending the regular rehabilitation program in Dekkerswald or CIRO and receiving NLPE. 6. No use of anabolic steroids during the inpatient pulmonary rehabilitation program in Dekkerswald and CIRO.
Exclusion criteria
Exclusion criteria: 1. Instable cardiac disease. 2. Participants treated with Neuromuscular Eletrical Stimulation (NMES) 3. History of drugs/alcohol abuse 4. Vegetarianism 5. Inability to understand the Dutch language 6. Self-reported beta-alanine supplementation in the past 3 months (wash-out period is set at 9 weeks). 7. Participation in pulmonary rehabilitation within the past 12 months. 8. Inability to perform the incremental shuttle walk test If the patient agrees to undergo a muscle biopsy, the following exclusion criterion will also apply: 9. Patients with bleeding disorders, a recent trauma of the muscle or an infection in the region of the proposed biopsy will be excluded for the muscle biopsies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary study parameter is exercise tolerance, determined with the endurance shuttle walk test as the walking endurance time. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary study parameters are cycle endurance time, lower-limb muscle function, muscle and systemic carnosine, taurine, beta-alanine and histidine, muscle and systemic oxidative stress and inflammation, dyspnoea, fatigue, physical activity, symptoms of anxiety and depression, body composition, cognitive function, respiratory muscle strength and disease-specific quality of life. Furthermore, the therapy adherence and patient safety will be assessed. | — |
Countries
Netherlands
Outcome results
None listed